Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 837 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ¿Tener paneles solares o vivir cerca de una granja solar puede... April 6, 2023 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... May 2, 2023 Bus Driver Wears Different Costume Each Day To Make Kids Smile... January 27, 2022 Hospice Nurse Fired from Job After Being Diagnosed with Breast Cancer September 30, 2019 Load more HOT NEWS Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions
